{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:13:53Z","timestamp":1774991633273,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12325-019-01063-9","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T19:53:31Z","timestamp":1566503611000},"page":"2811-2824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis"],"prefix":"10.1007","volume":"36","author":[{"given":"Mattias","family":"Lorentzon","sequence":"first","affiliation":[]},{"given":"Jaime","family":"Branco","sequence":"additional","affiliation":[]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[]},{"given":"Roland","family":"Chapurlat","sequence":"additional","affiliation":[]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Cortet","sequence":"additional","affiliation":[]},{"given":"Adolfo","family":"Diez-Perez","sequence":"additional","affiliation":[]},{"given":"Serge","family":"Ferrari","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Gasparik","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Herrmann","sequence":"additional","affiliation":[]},{"given":"Niklas Rye","family":"Jorgensen","sequence":"additional","affiliation":[]},{"given":"John","family":"Kanis","sequence":"additional","affiliation":[]},{"given":"Jean-Marc","family":"Kaufman","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Laslop","sequence":"additional","affiliation":[]},{"given":"M\u00e9d\u00e9a","family":"Locquet","sequence":"additional","affiliation":[]},{"given":"Radmila","family":"Matijevic","sequence":"additional","affiliation":[]},{"given":"Eugene","family":"McCloskey","sequence":"additional","affiliation":[]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[]},{"given":"Richard","family":"Pikner","sequence":"additional","affiliation":[]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[]},{"given":"Pawel","family":"Szulc","sequence":"additional","affiliation":[]},{"given":"Mila","family":"Vlaskovska","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-2226","authenticated-orcid":false,"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"1063_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","volume":"42","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42:467\u201375.","journal-title":"Bone"},{"key":"1063_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/joim.12369","volume":"277","author":"M Lorentzon","year":"2015","unstructured":"Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015;277:650\u201361.","journal-title":"J Intern Med"},{"key":"1063_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1532-5415.1992.tb01980.x","volume":"40","author":"RA Marottoli","year":"1992","unstructured":"Marottoli RA, Berkman LF, Cooney LM Jr. Decline in physical function following hip fracture. J Am Geriatr Soc. 1992;40:861\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"1063_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136.","journal-title":"Arch Osteoporos."},{"key":"1063_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385\u201397.","journal-title":"Osteoporos Int"},{"key":"1063_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S8756-3282(96)00383-3","volume":"20","author":"XG Cheng","year":"1997","unstructured":"Cheng XG, Lowet G, Boonen S, et al. Assessment of the strength of proximal femur in vitro: relationship to femoral bone mineral density and femoral geometry. Bone. 1997;20:213\u20138.","journal-title":"Bone"},{"key":"1063_CR7","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. World Health Organisation, pp 1\u2013129."},{"key":"1063_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11:25.","journal-title":"Arch Osteoporos."},{"key":"1063_CR9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","volume":"5","author":"R Eastell","year":"2017","unstructured":"Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5:908\u201323.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1063_CR10","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1210\/jc.2004-0164","volume":"89","author":"A Dovio","year":"2004","unstructured":"Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89:4923\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"1063_CR11","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809\u201322.","journal-title":"N Engl J Med"},{"key":"1063_CR12","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344\u201352.","journal-title":"JAMA."},{"key":"1063_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756\u201365.","journal-title":"N Engl J Med"},{"key":"1063_CR14","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1359\/jbmr.040116","volume":"19","author":"E McCloskey","year":"2004","unstructured":"McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res. 2004;19:728\u201336.","journal-title":"J Bone Miner Res"},{"key":"1063_CR15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S8756-3282(02)00728-7","volume":"30","author":"JA Clowes","year":"2002","unstructured":"Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002;30:886\u201390.","journal-title":"Bone"},{"key":"1063_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","volume":"26","author":"S Christgau","year":"2000","unstructured":"Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, et al. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone. 2000;26:505\u201311.","journal-title":"Bone"},{"key":"1063_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1302\/0301-620X.92B3.22787","volume":"92","author":"G Cox","year":"2010","unstructured":"Cox G, Einhorn TA, Tzioupis C, Giannoudis PV. Bone-turnover markers in fracture healing. J Bone Joint Surg Br. 2010;92:329\u201334.","journal-title":"J Bone Joint Surg Br"},{"key":"1063_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391\u2013420.","journal-title":"Osteoporos Int"},{"key":"1063_CR19","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, et al. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359\u201381.","journal-title":"Osteoporos Int"},{"key":"1063_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12:43.","journal-title":"Arch Osteoporos."},{"key":"1063_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19:399\u2013428.","journal-title":"Osteoporos Int"},{"key":"1063_CR22","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","volume":"49","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Cooper C, Eastell R, et al. International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011;49:1271\u20134.","journal-title":"Clin Chem Lab Med"},{"key":"1063_CR23","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","volume":"28","author":"P Szulc","year":"2017","unstructured":"Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET, National Bone Health Alliance Bone Turnover Marker P. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017;28:2541\u201356.","journal-title":"Osteoporos Int."},{"key":"1063_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cca.2016.06.036","volume":"467","author":"HA Morris","year":"2017","unstructured":"Morris HA, Eastell R, Jorgensen NR, et al. Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin Chim Acta. 2017;467:34\u201341.","journal-title":"Clin Chim Acta"},{"key":"1063_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/jbmr.5650110307","volume":"11","author":"P Garnero","year":"1996","unstructured":"Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337\u201349.","journal-title":"J Bone Miner Res"},{"key":"1063_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","volume":"27","author":"KE Naylor","year":"2016","unstructured":"Naylor KE, Jacques RM, Paggiosi M, et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016;27:21\u201331.","journal-title":"Osteoporos Int"},{"key":"1063_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jbspin.2011.05.003","volume":"79","author":"E Biver","year":"2012","unstructured":"Biver E, Chopin F, Coiffier G, et al. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis. Joint Bone Spine. 2012;79:20\u20135.","journal-title":"Joint Bone Spine."},{"key":"1063_CR28","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1210\/jc.2012-4113","volume":"98","author":"MR Sowers","year":"2013","unstructured":"Sowers MR, Zheng H, Greendale GA, et al. Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab. 2013;98:2854\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"1063_CR29","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1007\/s00198-016-3675-7","volume":"27","author":"EA Marques","year":"2016","unstructured":"Marques EA, Gudnason V, Lang T, et al. Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study. Osteoporos Int. 2016;27:3485\u201394.","journal-title":"Osteoporos Int"},{"key":"1063_CR30","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1210\/jc.2007-1508","volume":"93","author":"KK Ivaska","year":"2008","unstructured":"Ivaska KK, Lenora J, Gerdhem P, Akesson K, Vaananen HK, Obrant KJ. Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab. 2008;93:2622\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"1063_CR31","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1359\/jbmr.2000.15.7.1398","volume":"15","author":"A Rogers","year":"2000","unstructured":"Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res. 2000;15:1398\u2013404.","journal-title":"J Bone Miner Res"},{"key":"1063_CR32","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00198-008-0660-9","volume":"19","author":"P Szulc","year":"2008","unstructured":"Szulc P, Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 2008;19:1683\u2013704.","journal-title":"Osteoporos Int"},{"key":"1063_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/8756-3282(96)00102-0","volume":"19","author":"BJ Riis","year":"1996","unstructured":"Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone. 1996;19:9\u201312.","journal-title":"Bone"},{"key":"1063_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1359\/jbmr.070814","volume":"23","author":"J Finigan","year":"2008","unstructured":"Finigan J, Greenfield DM, Blumsohn A, et al. Risk factors for vertebral and nonvertebral fracture over 10\u00a0years: a population-based study in women. J Bone Miner Res. 2008;23:75\u201385.","journal-title":"J Bone Miner Res"},{"key":"1063_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1359\/jbmr.2000.15.1.20","volume":"15","author":"DW Dempster","year":"2000","unstructured":"Dempster DW. The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res. 2000;15:20\u20133.","journal-title":"J Bone Miner Res"},{"key":"1063_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.bone.2003.12.012","volume":"34","author":"H Follet","year":"2004","unstructured":"Follet H, Boivin G, Rumelhart C, Meunier PJ. The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone. 2004;34:783\u20139.","journal-title":"Bone"},{"key":"1063_CR37","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","volume":"15","author":"P Garnero","year":"2000","unstructured":"Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15:1526\u201336.","journal-title":"J Bone Miner Res"},{"key":"1063_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s001980050009","volume":"11","author":"PD Ross","year":"2000","unstructured":"Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int. 2000;11:76\u201382.","journal-title":"Osteoporos Int"},{"key":"1063_CR39","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1359\/JBMR.050609","volume":"20","author":"E Sornay-Rendu","year":"2005","unstructured":"Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20:1813\u20139.","journal-title":"J Bone Miner Res"},{"key":"1063_CR40","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","volume":"94","author":"H Johansson","year":"2014","unstructured":"Johansson H, Oden A, Kanis JA, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int. 2014;94:560\u20137.","journal-title":"Calcif Tissue Int"},{"key":"1063_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13018-019-1100-6","volume":"14","author":"A Tian","year":"2019","unstructured":"Tian A, Ma J, Feng K, et al. Reference markers of bone turnover for prediction of fracture: a meta-analysis. J Orthop Surg Res. 2019;14:68.","journal-title":"J Orthop Surg Res."},{"key":"1063_CR42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1359\/jbmr.091006","volume":"25","author":"KK Ivaska","year":"2010","unstructured":"Ivaska KK, Gerdhem P, Vaananen HK, Akesson K, Obrant KJ. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res. 2010;25:393\u2013403.","journal-title":"J Bone Miner Res"},{"key":"1063_CR43","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1210\/jc.2010-2878","volume":"96","author":"C Robinson-Cohen","year":"2011","unstructured":"Robinson-Cohen C, Katz R, Hoofnagle AN, et al. Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study. J Clin Endocrinol Metab. 2011;96:2186\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"1063_CR44","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jocd.2011.05.008","volume":"14","author":"EV McCloskey","year":"2011","unstructured":"McCloskey EV, Vasikaran S, Cooper C, Members FPDC. Official Positions for FRAX(R) clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). J Clin Densitom. 2011;14:220\u20132.","journal-title":"J Clin Densitom."},{"key":"1063_CR45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83\u201391.","journal-title":"Osteoporos Int."},{"key":"1063_CR46","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut 3rd","year":"2004","unstructured":"Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241\u20139.","journal-title":"J Bone Miner Res"},{"key":"1063_CR47","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535\u201341.","journal-title":"Lancet."},{"key":"1063_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/JBMR.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"Rosen CJ, Hochberg MC, Bonnick SL, et al. Treatment with once-weekly alendronate 70\u00a0mg compared with once-weekly risedronate 35\u00a0mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005;20:141\u201351.","journal-title":"J Bone Miner Res"},{"key":"1063_CR49","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051\u20136.","journal-title":"J Bone Miner Res"},{"key":"1063_CR50","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19:1250\u20138.","journal-title":"J Bone Miner Res"},{"key":"1063_CR51","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s00198-014-2787-1","volume":"25","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, McCloskey E, Branco J, et al. Goal-directed treatment of osteoporosis in Europe. Osteoporos Int. 2014;25:2533\u201343.","journal-title":"Osteoporos Int"},{"key":"1063_CR52","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","volume":"18","author":"JA Cramer","year":"2007","unstructured":"Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023\u201331.","journal-title":"Osteoporos Int"},{"key":"1063_CR53","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","volume":"28","author":"A Diez-Perez","year":"2017","unstructured":"Diez-Perez A, Naylor KE, Abrahamsen B, et al. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017;28:767\u201374.","journal-title":"Osteoporos Int."},{"key":"1063_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1742-1241.2008.01911.x","volume":"63","author":"P Bergmann","year":"2009","unstructured":"Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19\u201326.","journal-title":"Int J Clin Pract"},{"key":"1063_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222\u20139.","journal-title":"Bone"},{"key":"1063_CR56","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:530\u20137.","journal-title":"J Bone Miner Res"},{"key":"1063_CR57","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, et al. 10\u00a0years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513\u201323.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1063_CR58","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96:972\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"1063_CR59","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33:190\u20138.","journal-title":"J Bone Miner Res"},{"key":"1063_CR60","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/joim.12873","volume":"285","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M. Treating osteoporosis to prevent fractures: current concepts and future developments. J Intern Med. 2019;285:381\u201394.","journal-title":"J Intern Med"},{"key":"1063_CR61","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","volume":"28","author":"B Uebelhart","year":"2017","unstructured":"Uebelhart B, Rizzoli R, Ferrari SL. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int. 2017;28:2701\u20135.","journal-title":"Osteoporos Int"},{"key":"1063_CR62","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/jc.2015-4181","volume":"101","author":"DW Dempster","year":"2016","unstructured":"Dempster DW, Zhou H, Recker RR, et al. Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 2016;101:1353\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"1063_CR63","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","volume":"45","author":"SJ Glover","year":"2009","unstructured":"Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45:1053\u20138.","journal-title":"Bone"},{"key":"1063_CR64","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1359\/JBMR.050105","volume":"20","author":"P Chen","year":"2005","unstructured":"Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20:962\u201370.","journal-title":"J Bone Miner Res"},{"key":"1063_CR65","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","volume":"95","author":"JS Finkelstein","year":"2010","unstructured":"Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95:1838\u201345.","journal-title":"J Clin Endocrinol Metab"},{"key":"1063_CR66","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391:230\u201340.","journal-title":"Lancet"},{"key":"1063_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18110","volume":"18","author":"J Burch","year":"2014","unstructured":"Burch J, Rice S, Yang H, et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technol Assess. 2014;18:1\u2013180.","journal-title":"Health Technol Assess"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01063-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T23:32:28Z","timestamp":1597966348000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01063-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01063-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"21 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}